Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic

Jing-Xing Zhang1, Kai-Ge Zhou1, Yan-Xin Yin2

  • 1Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

Experimental Gerontology
|November 27, 2022
PubMed
Abstract

Insights

Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects against Parkinson's Disease (PD) by reducing neuroinflammation and dopaminergic neuron loss. This study shows MANF activates the AKT/GSK3β-Nrf-2 pathway, mitigating PD-related neurodegeneration.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cell Biology

Background:

  • Microglial activation in Parkinson's Disease (PD) releases inflammatory factors, causing neuronal loss.
  • Mesencephalic astrocyte-derived neurotrophic factor (MANF) shows promise in promoting neuronal survival in PD models.
  • The precise impact of MANF on neuroinflammation in PD remains largely uncharacterized.

Purpose of the Study:

  • To investigate the protective effects of high MANF expression against neuroinflammation-induced dopaminergic neurodegeneration in a rat model of PD.
  • To elucidate the underlying mechanisms of MANF's neuroprotective and anti-neuroinflammatory actions in PD.

Main Methods:

  • Adeno-associated virus serotype 8 carrying MANF (AAV8-MANF) was used to overexpress MANF in a 6-hydroxydopamine (6-OHDA) induced PD rat model.
  • Behavioral tests (Rotarod), immunofluorescence, and Western blotting were employed to assess neuroprotection and neuroinflammation.
  • In vitro studies utilized 6-OHDA-treated SH-SY5Y cells and lipopolysaccharide (LPS)-treated BV-2 cells to analyze MANF's mechanisms.

Main Results:

  • AAV8-MANF administration significantly improved motor function and protected dopaminergic neurons in 6-OHDA rats.
  • MANF reduced microglial activation (attenuated CD11b upregulation) and apoptosis.
  • MANF upregulated key proteins in the AKT/GSK3β-Nrf-2 signaling pathway (p-AKT, p-GSK3β, Nrf-2, BCL-2) and reduced pro-inflammatory cytokines (TNF-α, IL-6).

Conclusions:

  • MANF effectively prevents dopaminergic neurodegeneration in PD models.
  • MANF exerts its protective effects by inhibiting microglia activation and reducing neuroinflammation.
  • The AKT/GSK3β-Nrf-2 signaling axis is a critical pathway mediating MANF's neuroprotective actions in PD.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
345
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
660
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K